Latest News

Latest news and updates directly from our blog.
bt_bb_section_bottom_section_coverage_image
Supporting ClinSpec Diagnostics Ltd

Norcliffe Capital are proud to support ClinSpec Diagnostics Ltd and the future of cancer diagnostics. ClinSpec Dx, a Glasgow based spin out from the University of Strathclyde, have developed a cancer diagnostics system using a simple blood test analysis to accelerate the time it takes to diagnose cancer. Based on the world-leading research of Dr Matthew Baker,...

Completion of a £6 million fundraise for Biosceptre International.

Norcliffe Capital are pleased to announce the completion of a £6 million fundraise for Biosceptre International. Biosceptre International are developing groundbreaking CAR T cancer therapeutics with a unique target that is only found on cancer cells, not normal cells, that should mitigate the usual side effects associated with cancer treatments. Biosceptre is such an exciting...

NeedleSmart Pro receives FDA approval

NeedleSmart Limited have achieved FDA approval for their NeedleSmart Professional device as a Class II medical device. The NeedleSmart Pro destroys a hypodermic needle, post procedure, by heating the needle to 1300 degrees and compressing it into a sterile, non-sharp sphere. This reduces the risk of needlestick injuries and significantly reduces disposal costs. The NeedleSmart...

Afon technology, a small firm in Wales has had a huge breakthrough in the management of diabetes. They have patented a real-time, non-invasive blood glucose monitor that will benefit millions of diabetes sufferers the world over. In fact there are over 422 Million of them.. Host Frankie Picasso speaks to their CEO, Inventor and Quality...